A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiation for recurrent head and neck cancers

Gozde Yazici, Tolga Yusuf Sanli, Mustafa Cengiz, Deniz Yuce, Melis Gultekin, Pervin Hurmuz, Ferah Yıldız, Faruk Zorlu, Fadil Akyol, Murat Gurkaynak and Gokhan Ozyigit*

Abstract

Background: This study aimed to compare the therapeutic outcomes and fatal carotid blow out syndrome (CBOS) incidence rates between two different stereotactic body radiotherapy (SBRT) protocols.

Methods: The study included 75 patients with inoperable locally recurrent head and neck cancer treated with SBRT in our department between June 2007 and March 2011. The first 43 patients were treated sequentially (group I). Then our SBRT protocol was changed due to the high rate of CBOS, and the following 32 patients were treated every other day in a prospective institutional protocol (group II).

Results: Median overall survival in group I and group II was 11 months and 23 months, respectively (P = 0.006). We observed 11 cases of CBOS. Only 1 of 7 patients (14%) with CBOS survived in group I, whereas 2 of 4 patients (50%) in group II remain alive. CBOS free median overall survivals were 9 months, and 23 months in group I and group II respectively (P = 0.002). The median radiation dose received by the carotid artery in patients with CBOS was 35.6 Gy (range: 34–42.8 Gy), versus 34.7 Gy (range: 0–44 Gy) in the patients that didn’t have CBOS (P = 0.15). CBOS did not occur in any of the patients with a maximum carotid artery radiation dose <34 Gy.

Conclusions: Every other day SBRT protocol for re-irradiation of recurrent head and neck cancer is promising in terms of decreasing the incidence of fatal CBOS.

Keywords: Stereotactic radiotherapy, Reirradiation, Head and neck cancer, CyberKnife, Fractionation

Background

The rate of local recurrence or persistent disease in patients with locally advanced head and neck cancer is 3%-50%, despite the use of multidisciplinary treatment modalities [1-3]. Treatment choices for such patients are sparse and outcomes are not satisfactory. The prognosis is reported to be better in patients undergoing surgery, which can be performed in only a minority of patients [4-6]. Even when surgery is performed additional local treatment is necessary because of the high rate of local recurrence [4-8].

Re-irradiation is associated with an increase in local control and overall survival. Three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) series have reported local control rates of 60%-70% for re-irradiation in patients with recurrent head and neck cancer; however, the occurrence of serious toxicity was high (10%-40%) [9-11]. Stereotactic body radiotherapy (SBRT) is a relatively new technique for re-irradiation of recurrent head and neck cancer. SBRT facilitates administration of high doses of radiation to the tumor while offering maximal protection to adjacent organs. We recently reported the results of SBRT in this group of patients [12]. Although our local control rate was higher than that in IMRT series, the occurrence of carotid blowout syndrome (CBOS) was relatively high, and as such we subsequently altered our SBRT protocol. The present study aimed to compare the local control rate, overall survival rate, and toxicity rate of the 2 SBRT protocols (our previously reported and newer protocols) for re-irradiation in patients with locally recurrent head and neck cancer.
Furthermore, we particularly assessed whether fatal CBOS incidence changed after every other day SBRT schedule.

**Methods**

The study included 75 patients with inoperable recurrent head and neck cancer that were treated with SBRT in our department between June 2007 and March 2011. The first 43 patients were treated sequentially (group I), and then our SBRT protocol was changed due to the high rate of CBOS, so the following 32 patients were treated every other day in a prospective institutional protocol (group II). The study protocol was approved by the Hacettepe University Faculty of Medicine Institutional Review Board, and written informed consent was obtained from all the patients before undergoing re-irradiation. Distant metastasis was ruled out based on bone scintigraphy, thoracic computed tomography (CT), abdominal CT, or positron emission tomography (PET) findings. All local instances of recurrence were confirmed either radiologically or histopathologically.

Patients were immobilized using a head and neck thermoplastic mask. CT and magnetic resonance imaging (MRI) (slice thickness: 1 mm) were performed with the patients in the treatment position. The images obtained were then fused for contouring. Gross tumor volume (GTV) was delineated as the planning target volume (PTV). Multiplan (Accuray Inc., Sunnyvale, CA) software was used for inverse planning. The treatments were delivered via a CyberKnife (Accuray Inc., Sunnyvale, CA).

We previously reported that there was a significant risk of CBOS in patients whose carotid arteries were surrounded by the tumor >270° circumferentially [12]; therefore, we used CT angiography to follow-up this particular subgroup of patients. All patients were informed briefly about the importance of nasal bleeding and were told to contact us immediately if they experienced any bleeding—even minor bleeding. Patients were followed-up monthly for the first 3 months post SBRT, and then every 3 months for 2 years.

Overall survival, progression free survival, and survival curves were computed using the Kaplan-Meier method and compared by Cox-Mantel log-rank test. All statistical analysis was performed using the SPSS 15.0 software.

**Results**

Patient characteristics are summarized in Table 1. Median age of all the patients was 53 years (range: 15–87 years). There wasn’t a significant difference in demographic or clinical characteristics between the 2 groups. The most common site of re-irradiation was the nasopharynx (n = 34 patients), followed by the oral cavity and larynx. The SBRT treatment characteristics are given in Table 2. Median overall survival was 14 months (range: 10.8-17.2 months) for all patients. Median overall survival in group I and group II was 11 months and 23 months, respectively (P = 0.006) (Figure 1). The overall survival rate in group I and group II was 42% and 84% at 12 months, and 23% and 38% at 24 months, respectively. Median CBOS free overall survival was 9 months (range: 6.5-11 months) in group I, and was 23 months (range: 10.8-38.1 months) in group II (P = 0.002).

Complete response was achieved in 12 patients (16%), 17 patients (22.7%) had partial response, and stable disease was observed in 29 patients (38.7%). Ultimate local control was achieved in 77.4% of the patients. The local control rate was 67.5% in group I, versus 90.6% in group II (P = 0.029). Progression-free survival was 13 months for all patients, 9 months in group I, and 18 months in group II (P = 0.004) (Figure 2). Tumor size was considered to be possible prognosticator. However, we could not detect any significant difference in time to progression, overall survival, or risk of bleeding between the patients with GTV ≤52 versus GTV >52 mL.

The most common grade II and higher toxicities were dysphagia (16%) and CBOS (14.7%). Dysphagia was observed in 10 patients (23%) in group I, versus 3 patients (6.3%) in group II (P = 0.047). In all, 7 patients (16%) in group I had CBOS, but only 1 of them survived, whereas 4 patients (12.5%) in group II had CBOS and to date 2 remain alive. The median radiation dose received by the carotid artery in patients with CBOS was 36.5 Gy (range: 34–42.8 Gy), versus 34.7 Gy (range: 0–44 Gy) in the patients that didn’t have CBOS (P = 0.15). CBOS did not

Table 1 Patient characteristics

| Sex (n)                   | Group 1 | Group 2 | P  |
|--------------------------|---------|---------|----|
| -Female                   | 22      | 9       | 0.03|
| -Male                     | 21      | 23      |    |
| Age at SBRT (years)       |         |         |    |
| -Minimum and maximum      | 19-87   | 15-83   | >0.05|
| -Median                   | 53      | 57      |    |
| SBRT site (n)             |         |         |    |
| -Nasopharynx              | 19      | 15      | >0.05|
| -Oral cavity              | 8       | 4       |    |
| -Paranasal                | 8       | 3       |    |
| -Larynx                   | 4       | 8       |    |
| -Hypopharynx              | 4       | 2       |    |
| Dose of primary radiation (Gy) |       |         |    |
| -Minimum and maximum      | 30-77.4 | 38-78   | >0.05|
| -Median                   | 65      | 64      |    |
| Time between primary radiation treatment and SBRT (months) | | |
| -Minimum and maximum      | 9-232   | 10-300  | >0.05|
| -Median                   | 35      | 36      |    |
occur in any of the patients with a maximum carotid artery radiation dose <34 Gy. The treatment characteristics of patients with CBOS are given in Table 3. The biologic effective dose (BED) for late responding tissues assuming an α/β ratio of 3 were calculated for the SBRT scheme and for the cumulative dose received by the patient. The median BED of SBRT were 95 Gy\(_3\) and 92 Gy\(_3\) for patients with and without CBOS respectively (p = 0.8). The cumulative BED was 203 Gy\(_3\) in patients with CBOS whereas it was 198 Gy\(_3\) in patients without CBOS (p = 0.7).

The circumference of the carotid artery entrapped by the tumor was calculated in each patient; median carotid artery wall entrapment by the tumor in all patients was 180°, versus 270° in the patients that had bleeding were considered. CBOS was not observed in patients with lesions entrapping <180° of the carotid artery.

### Discussion

Current study compared 2 SBRT protocols for re-irradiation in locally recurrent head and neck cancer patients in terms of therapeutic outcomes and toxicity. We demonstrated that a simple strategy change in fractionation

---

**Table 2 Treatment characteristics**

| Treatment characteristics       | Group 1   | Group 2   | P   |
|----------------------------------|-----------|-----------|-----|
| SBRT dose (Gy)                   |           |           |     |
| - Range                          | 25-35     | 15-35     |     |
| - Median                         | 30        | 30        |     |
| Target volume (mL)               |           |           |     |
| - Range                          | 4-214     | 5-166     | 0.551 |
| - Median                         | 54        | 46        |     |
| Number of fractions              |           |           |     |
| - Range                          | 3-5       | 4-6       |     |
| - Median                         | 5         | 5         |     |
| Carotid artery dose (Gy)         |           |           |     |
| - Range                          | 25-42.5   | 68-39.1   | >0.05  |
| - Median                         | 35        | 34.9      |     |
| Temporomandibular joint dose (Gy)|           |           |     |
| - Range                          | 0-42      | 0-33.5    | 0.217  |
| - Median                         | 24        | 14.7      |     |
| Temporal lobe dose (Gy)          |           |           |     |
| - Range                          | 0-44.1    | 0-35.9    |     |
| - Median                         | 21.7      | 21.5      |     |
| Conformity index                 |           |           |     |
| - Range                          | 1.1-2.46  | 1.14-2.23 |     |
| - Median                         | 1.57      | 1.54      |     |
| Homogeneity index                |           |           |     |
| - Range                          | 1.14-1.67 | 1.15-1.43 |     |
| - Median                         | 1.32      | 1.28      |     |
| Prescribed isodose (Gy)          |           |           |     |
| - Range                          | 60-88     | 70-87     |     |
| - Median                         | 77        | 78        |     |
| Collimator size (mm)             |           |           |     |
| - Range                          | 10-40     | 12.5-35   |     |
| - Median                         | 20        | 20        |     |
| Beam number                      |           |           |     |
| - Range                          | 142-369   | 121-481   |     |
| - Median                         | 206       | 200       |     |
dramatically increase survival and decrease fatal CBOS and other serious SBRT related toxicities. The 2-year overall survival rate in every other day protocol is among the best to be reported in the literature.

With conformal radiotherapy or IMRT modalities radiation doses of 60 Gy resulted in response rates of 60%-70% in patients with recurrent head and neck cancer; however, the occurrence of grade 3 or higher serious late effects was also high (40%) [10,11,13]. There is a growing body of evidence for re-irradiation of head and neck cancer patients with SBRT protocols. George et al. reported a 26% local control rate and 22% overall survival rate without grade 4 or higher side effects in response to doses of 20–30 Gy administered in 5 fractions [14]. Another study that included 36 patients with recurrent head and neck cancer that were re-irradiated with a median dose of 30 Gy in 3–5 fractions reported that the 1-year local control rate was 61%, but that grade 3 or higher side effects occurred in 37% of patients [14]. In an earlier study we compared 3D-CRT and SBRT in 51 recurrent nasopharyngeal cancer patients; the 2-year local control rate was similar in both groups (80% versus 82%), but serious late effects were significantly less common in the SBRT group (48% versus 21%, P < 0.05) [15]. Furthermore we noticed that fatal CBOS rates were much higher than the previously reported reirradiation series [16-18]. Since we used very high dose per fraction in a previously irradiated patient the interval between two consecutive fractions might be inadequate in terms of sublethal damage repair in critical tissues. In the light of this hypothetical idea, which is also supported by the study of King et al. as they showed that every other day protocol resulted in a reduced rectal toxicity rate in prostate cancer patients treated with SBRT, we decided to change our SBRT fractionation schedule by increasing the interval between fractions [19]. Consequently we observed that group II fared better than sequential group in terms of toxicities, particularly in terms of fatal CBOS. In a recent article Yamazaki et al. concluded that the every other day treatment may have a potential impact on adverse toxicities as most papers reporting CBOS used SBRT in consecutive days [20]. Our results supports the idea by Yamazaki et al., but in contrast to the literature we observed CBOS also in every other day treatment group [21,22].

The current BED formula has not been validated for the large doses per fraction however it is used to evaluate different schemas in terms of adverse reactions. We calculated the BED for late responding tissues in order to reach a cut off value for the CBOS. However, we couldn’t find a specific cut-off point for the carotid artery cumulative dose.

It may be argued that the median follow up time for every other day protocol was inadequate to asses CBOS. However, it is noteworthy that all cases of CBOS were observed in the first year of SBRT in group I, and minimum follow up was longer than 1 year with a median follow up of 23 months in group II. It seems that the decrease in fatal CBOS incidence resulted in an increase in OS rates of patients in group II.

We previously reported that tumor surrounding >180° of the carotid artery are associated with a significantly elevated risk of bleeding in stereotactic re-irradiation of recurrent head and neck cancer. In current study we performed further analysis on the relationship between the carotid artery radiation dose and the risk of bleeding. We noticed that all patients with bleeding had a median carotid artery radiation dose above 34 Gy. Likewise, none of the patients with a tumor surrounding <180° of the carotid artery experienced bleeding. Therefore clinicians should be aware of dose limits of carotid arteries to prevent that fatal complication.

Table 3 Clinical and treatment characteristics of patients with carotid blow-out syndrome

| Patient number | SBRT scheme | GTV volume (ml) | SBRT site | Dose of primary radiotherapy (Gy) | SBRT dose (Gy)/fx number | Maximum carotid artery point dose (Gy) | Local control |
|----------------|-------------|-----------------|-----------|-----------------------------------|--------------------------|--------------------------------------|--------------|
| 1              | I           | 157             | Hypopharynx | 60                                | 30/5                     | 41.8                                  | Complete response |
| 2              | I           | 173             | Retromolar trigone | 60                                | 35/5                     | 59                                    | Progression |
| 3              | I           | 130             | Larynx    | 60                                | 30/5                     | 39.4                                  | Complete response |
| 4              | I           | 29              | Nasopharynx | 70                                | 35/5                     | 46.6                                  | Partial response |
| 5              | I           | 101             | Nasopharynx | 66                                | 30/5                     | 38.5                                  | Complete response |
| 6              | I           | 37              | Nasopharynx | 65                                | 30/5                     | 37.5                                  | Progression |
| 7              | I           | 50              | Nasopharynx | 66                                | 32/5                     | 40.7                                  | Stable       |
| 8              | II          | 55              | Nasopharynx | 66                                | 32/6                     | 46                                    | Partial response |
| 9              | II          | 127             | Larynx    | 70                                | 30/5                     | 37.5                                  | Stable       |
| 10             | II          | 30              | Hypopharynx | 64                                | 30/5                     | 41                                    | Stable       |
| 11             | II          | 51              | Oral cavity | 70                                | 30/5                     | 38.5                                  | Stable       |

GTV: gross tumor volume, Gy: gray, fx: fraction, SBRT: stereotactic body radiotherapy, I: consecutive day, II: every other day.
Conclusion
In the absence of a prospective randomized trial, our current institutional SBRT protocol for re-irradiation of locally recurrent head and neck cancer is to treat patients every other day. If an individual SBRT plan violates the limits of the carotid artery dose mentioned above or the tumor entraps the carotid artery more than 180°, we recommend IMRT with conventional fractionation. However, further prospective trials are required to clarify both the role of SBRT and the optimal fractionation regimen in locally recurrent head and neck cancers.

Competing interests
The authors report no actual or potential conflicts of interest relevant to the material presented herein.

Authors’ contributions
GO is the principal investigator, planned the design of the study and helped to draft the manuscript. DY drafted the manuscript, participated in the design, performed the statistical analysis. MC have made substantial contributions to conception and design. DY participated in analysis and interpretation of data. MG, PH, FY, FZ, FA, MG revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by a Hacettepe University research grant (1–05 A 101 009).

Received: 2 August 2013 Accepted: 15 October 2013 Published: 18 October 2013

References
1. Perez CA, Devinein VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N: Carcinoma of the nasopharynx: factors affecting prognosis. J Int Radiat Oncol Biol Phys 1992, 23:271–280.
2. Heron DE, Ferris RL, Karamouzis M, Andrade RS, Deeb EL, Burton S, Gooding WE, Branstetter BF, Mountz JM, Johnson JT, et al: Stereotactic body radiotherapy for recurrent squamous carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009, 75:1493–1500.
3. Roh KW, Jang JS, Kim MS, Sun DI, Kim BS, Jung SH, Kang JH, Yoon SC, Jang HS, et al: Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009, 74:1348–1355.
4. Johansen LV, Gou C, Overgaard J: Supraglottic carcinoma: patterns of failure and salvage treatment after curatively intended radiotherapy in 410 consecutive patients. Int J Radiat Oncol Biol Phys 2002, 53:948–958.
5. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR: Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx. Int J Radiat Oncol Biol Phys 1995, 32:605–609.
6. Taussky D, Dulgurov P, Allal AS: Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. Head & Neck 2005, 27:182–186.
7. Temann S, Koka V, Marnelle G, Julieron M, Carmantrant R, Marandas P, Janot F, Bouthin J, Lubois C: Treatment of the N0 neck during salvage surgery after radiotherapy of head and neck squamous cell carcinoma. Head & Neck 2005, 27:653–658.
8. Janot F, De Raurcou D, Benhamou E, Ferron C, Dolivet G, Benadoun RJ, Hamoir M, Gery B, Julieron M, Castaign M, et al: Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008, 26:5318–5323.
9. Salama JK, Vokes EE: Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Seminars in oncology 2008, 35:251–261.
10. Biagioli MC, Harvey M, Roman E, Raez LE, Wolfson AH, Mutyala S, Han HS, Markoe A: Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:1067–1073.
11. Lee N, Chan K, Bekelman JE, Zhung J, Mechalakos J, Narayana A, Wolden S, Venkatraman ES, Pfister D, Kraus D, et al: Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 68:731–740.
12. Cengiz M, Gazyigit G, Yazici G, Dogan A, Yildiz F, Zorlu F, Gurkanay M, Gullu H, Hosal S, Aykol F: Salvage reirradiation with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011, 81:104–109.
13. Langier CJ, Harris J, Horwitz EM, Nicolau N, Kies M, Curnan W, Wong S, Ang K: Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of radiation therapy oncology group protocol 9911. J Clin Oncol 2007, 25:4800–4805.
14. Voyvoy G, Heron DE, Burton S, Grandis J, Quinn A, Ferris R, Ozhasoglu C, Vogel W, Johnson J: Frameless stereotactic radiosurgery for recurrent head and neck carcinoma. Technol Cancer Res Treat 2006, 5:529–535.
15. Gazyigit G, Cengiz M, Yazici G, Yildiz F, Gurkanay M, Zorlu F, Yildiz D, Hosal S, Gullu I, Aykol F: A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2011, 81:e263–e268.
16. McDonald MW, Moore MG, Johnstone PA: Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int J Radiat Oncol Biol Phys 2012, 82:1083–1089.
17. Salama JK, Vokes EE, Chmura SJ, Milano MT, Kao J, Stenson KM, Witt ME, Haraf DJ: Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006, 64:382–391.
18. Xiao J, Xu G, Miao Y: Fractionated stereotactic radiosurgery for 50 patients with recurrent or residual nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2011, 81:1164–1170.
19. King CR, Brooks JO, Gill H, Pawlicki T, Cotsart C, Presti JC: Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 78:1043–1048.
20. Yamazaki H, Ogita M, Koda M, Nakamura S, Inoue H, Himeji K, Kotsuma T, Yoshida K, Yoshikawa Y, Yamashita K, Udono H: Frequency, outcome and prognostic factors of carotid blowout syndrome after hypofractionated re-irradiation of head and neck cancer using CyberKnife: a multi-institutional study. Radiat Oncol 2013, 8:305–309.
21. Rwigema JC, Heron DE, Ferris RL, Gibson M, Quinn A, Yang Y, Ozhasoglu C, Burton S: Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Am J Clin Oncol 2010, 33:286–293.
22. Vargo JA, Heron DE, Ferris RL, Rwigema JC, Kalash R, Wegner RE, Ohr J, Burton S: Examining tumor control and toxicity following stereotactic body radiotherapy in locally-recurrent, previously-irradiated head-and-neck cancers: Implications of treatment duration and tumor volume. Head & Neck 2013; doi:10.1002/hed.23462. Epub ahead of print.

Cite this article as: Yazici et al.: A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiation for recurrent head and neck cancers. Radiation Oncology 2013; 8:242.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit